Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

Christina Berens, Heiko Rühl, MD, Jens Müller, Johannes Oldenburg, MD PhD, Peter Brossart, MD, Dominik Wolf, MD, Bernd Pötzsch

Blood (2018) 132 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2018-99-118487

Published: 2018

Journal Articles

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Beatrice Nolan, Johnny Mahlangu, Guy Young, Barbara A Konkle, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Johannes Oldenburg, MD PhD, Keiji Nogami, MDPhD, Nikola Tripkovic, Huixing Yuan, Dan Rudin

Blood (2018) 132 (Supplement 1): 1192.

https://doi.org/10.1182/blood-2018-99-118586

Published: 2018

Journal Articles

Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B

Yasmina L. Abajas, MD, Paul Edward Monahan, MD, Brenda Nielsen, RN, Pia Petrini, MD, Susanna Ranta, MD PhD, Geoffrey A. Allen, MD, Silvia Horneff, MD, Annika Martensson, MD PhD, Johannes Oldenburg, MD PhD, Rolf Ljung, MD PhD Professor

Blood (2018) 132 (Supplement 1): 1193.

https://doi.org/10.1182/blood-2018-99-120141

Published: 2018

Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD

Blood (2018) 132 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2018-99-110608

Published: 2018

Journal Articles

The Variable Clinical Expressivity of Factor V Leiden, but Not of Prothrombin G20210A, Correlates with the Extent of the APC Response to In Vivo Thrombin Formation

Heiko Rühl, MD, Christina Berens, Sara Reda, Franziska Isabelle Winterhagen, Jens Müller, Johannes Oldenburg, MD, Peter Hanfland, Bernd Pötzsch

Blood (2018) 132 (Supplement 1): 1221.

https://doi.org/10.1182/blood-2018-99-115949

Published: 2018

Journal Articles

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

Víctor Jiménez-Yuste, Dr, Johannes Oldenburg, MD PhD, Savita Rangarajan, MBBS, FRCP, FRCPath, Roser Peiró, PhD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2282.

https://doi.org/10.1182/blood.V126.23.2282.2282

Published: 2015

Journal Articles

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Guy Young, MD, Peter W. Collins, MD, Ramin Tehranchi, MD, PhD, Ampaiwan Chuansumrit, Hideji Hanabusa, MD, Steven R. Lentz, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, MD PhD, Turkan Patiroglu, MD, Elena Santagostino, MD PhD, Marek Zak, Fara Abdul Karim

Blood (2014) 124 (21): 2846.

https://doi.org/10.1182/blood.V124.21.2846.2846

Published: 2014

Journal Articles

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

Kirstin Sandrock-Lang, PhD, Johannes Oldenburg, MD PhD, Verena Wiegering, MD, Susan Halimeh, MD, Sentot Santoso, Karin Kurnik, Lars Fischer, Dimitrios Tsakiris, MD, Michael Sigl-Kraetzig, Brigit Brand, MD, Katharina Kraetzer, Niklas Deeg, Eileen Busse, Zieger Barbara

Blood (2014) 124 (21): 1460.

https://doi.org/10.1182/blood.V124.21.1460.1460

Published: 2014

Journal Articles

The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients

Heiko Rühl, MD, Jens Müller, PhD, Johannes Oldenburg, MD PhD, Bernd Pötzsch, MD PhD

Blood (2014) 124 (21): 1475.

https://doi.org/10.1182/blood.V124.21.1475.1475

Published: 2014

Journal Articles

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Katsuyuki Fukutake, MD PhD, Manual Carcao, MD, Aida Inbal, MD, Bryce A. Kerlin, MD, Johannes Oldenburg, MD PhD, Anders Rosholm, MSc, PhD, May-Lill Garly, MD PhD, Diane J. Nugent, MD

Blood (2014) 124 (21): 1520.

https://doi.org/10.1182/blood.V124.21.1520.1520

Published: 2014

Journal Articles

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Anna Pavlova, MD PhD, Irina Matytsina, Morio Arai, MD, Johannes Oldenburg, MD PhD

Blood (2014) 124 (21): 1527.

https://doi.org/10.1182/blood.V124.21.1527.1527

Published: 2014

Journal Articles

Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A

Andreas Tiede, MD, PhD, Sigurd Knaub, PhD, Johannes Oldenburg, MD, Johann Bichler, PhD

Blood (2013) 122 (21): 3595.

https://doi.org/10.1182/blood.V122.21.3595.3595

Published: 2013

Journal Articles

Natural History Of Hemophilic Joint Disease Using Sensitive Imaging With Magnetic Resonance Imaging (MRI)

Thomas J Glorioso, MS, John M Kittelson, PhD, Michael L Manco-Johnson, MD, Bjorn Lundin, MD, PhD, Walter Hong, MD, Johannes Oldenburg, MD, Taylor A Blades, BS, Marilyn J. Manco-Johnson, MD

Blood (2013) 122 (21): 209.

https://doi.org/10.1182/blood.V122.21.209.209

Published: 2013

Journal Articles

Genetic Background in Patients with Severe Factor XIII A-Subunit Deficiency Treated with Recombinant FXIII

Vytautas Ivaskevicius, MD, Arijit Biswas, MD, Anne Thomas, MD, Ramin Tehranchi, M.D., Ph.D., Johannes Oldenburg, MD

Blood (2012) 120 (21): 1125.

https://doi.org/10.1182/blood.V120.21.1125.1125

Published: 2012

Journal Articles

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Yohann Repesse, PhD, Ivan Peyron, Jordan Dimitrov, PhD, Suryasarathi Dasgupta, PhD, Elika Farrokhi Moshai, Annie Borel-Derlon, MD, PhD, Catherine Costa, MD, Benoist Guillet, MD, PhD, Roseline d'Oiron, MD, Achille Aouba, MD, Chantal Rothschild, MD, Johannes Oldenburg, MD, Ana Pavlova, MD, Srinivas Kaveri, D. V. M., Ph.D, Sebastien Lacroix-Desmazes, PhD

Blood (2012) 120 (21): 38.

https://doi.org/10.1182/blood.V120.21.38.38

Published: 2012

Journal Articles

Rescue and Primary ITI in Children and Adults with a Single FVIII/VWF Product

Louis M. Aledort, MD, Johannes Oldenburg, MD, Elena Santagostino, MD, PhD, Victor Jimenez Yuste, MD PhD

Blood (2012) 120 (21): 1174.

https://doi.org/10.1182/blood.V120.21.1174.1174

Published: 2012

Journal Articles

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Sigurd Knaub, PhD, Toshko Lissitchkov, MD, PhD, Kingsley Hampton, Mario Von Depka, Savita Rangarajan, MBBS, FRCP, FRCPath, Charles R.M. Hay, MD, FRCP, FRCPath, Edward GD Tuddenham, MBBS, FRCP, FRCPath, PhD, Peter Collins, MD, Katharina Holstein, MD, Angela Huth-Kühne, Ingrid Pabinger, MD, Johannes Oldenburg, MD, Johann Bichler

Blood (2012) 120 (21): 1132.

https://doi.org/10.1182/blood.V120.21.1132.1132

Published: 2012

Journal Articles

Recombinant Factor XIII, Safe and Novel Treatment for Congenital Factor XIII Deficiency

Aida Inbal, MD, Johannes Oldenburg, MD, Manuel Carcao, MD, BSC, Anders Rosholm, MSc, PhD, Ramin Tehranchi, MD, PhD, Diane J Nugent, MD

Blood (2010) 116 (21): 20.

https://doi.org/10.1182/blood.V116.21.20.20

Published: 2010

NARROW

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

The Variable Clinical Expressivity of Factor V Leiden, but Not of Prothrombin G20210A, Correlates with the Extent of the APC Response to In Vivo Thrombin Formation

Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients

New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency

Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII

Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A

Natural History Of Hemophilic Joint Disease Using Sensitive Imaging With Magnetic Resonance Imaging (MRI)

Genetic Background in Patients with Severe Factor XIII A-Subunit Deficiency Treated with Recombinant FXIII

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Rescue and Primary ITI in Children and Adults with a Single FVIII/VWF Product

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Recombinant Factor XIII, Safe and Novel Treatment for Congenital Factor XIII Deficiency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only